From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
OC subtype | Molecular alteration in the PI3K pathway |
---|---|
High-grade serous | PIK3CA amplification (25%) |
PIK3CA mutation (<3%) | |
PIK3R1 mutation or copy number loss (2%) | |
AKT1/2/3 amplification (15%) | |
PTEN copy number loss (5%) | |
TSC1/2 mutation or loss (4%) | |
LKB1 (aka STK11) loss or mutation (2%) | |
Low-grade serous | Rare |
Mucinous | Rare |
Endometrioid | PIK3CA mutation (20%) |
PTEN loss (40%) | |
Clear cell | PIK3CA mutation (35%) |